Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mannuronic acid oligose with carboxyl at 1-position of reducing end and derivative to treatment of Parkinson's disease

A technology of uronic acid oligosaccharides and derivatives, which is applied in the preparation of sugar derivatives, sugar derivatives, and sugar derivatives, and can solve the problems of drug application restrictions and large molecular weight of alginate

Inactive Publication Date: 2017-01-25
GREEN VALLEY (SHANGHAI) PHARM CO LTD
View PDF6 Cites 37 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, due to the large molecular weight of alginate, its application in medicine is limited to a certain extent.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mannuronic acid oligose with carboxyl at 1-position of reducing end and derivative to treatment of Parkinson's disease
  • Application of mannuronic acid oligose with carboxyl at 1-position of reducing end and derivative to treatment of Parkinson's disease
  • Application of mannuronic acid oligose with carboxyl at 1-position of reducing end and derivative to treatment of Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Preparation of Alginate Oligosaccharides

[0045] Weigh 1 g of polymannuronic acid sodium salt (weight average molecular weight 8235 Da, provided by Shanghai Green Valley Pharmaceutical Co., Ltd.), and add appropriate amount of distilled water to prepare a 1% (weight percent) aqueous solution of polymannuronate sodium. The pH value of the 1% aqueous sodium polymannuronate solution was adjusted to 4 with hydrochloric acid, and then the aqueous solution was placed in an autoclave. The reaction was heated at 110°C for 4 hours. The reacted solution was taken out from the autoclave and allowed to cool. After cooling, the pH value of the reacted solution was adjusted with NaOH solution to obtain a neutral liquid. Under the condition of stirring, the neutral liquid was slowly added into ethanol in an amount 4 times the volume of the liquid, alcohol precipitation was carried out and the mixture was allowed to stand overnight. The solid matter obtained by alcohol pr...

Embodiment 2

[0047] Example 2 Preparation of algin oligosaccharide oxygen hydrolysis product

[0048] Take 5 g of the above-mentioned crude alginate oligosaccharides that have not been separated by molecular exclusion chromatography to prepare a 5% (weight percent) aqueous solution. Fresh oxidant copper hydroxide was prepared by adding 25 ml of 5% (weight percent) copper sulfate solution to 50 ml of 10% (weight percent) sodium hydroxide solution and mixing immediately. The fresh oxidant copper hydroxide was immediately added to 40ml of the above-mentioned 5% (weight percent) alginate oligosaccharide solution, and heated in a boiling water bath until no brick-red precipitate was produced. The reaction system was centrifuged to remove precipitates to obtain a supernatant. Get a little supernatant and add the oxidizing agent again to check whether there is brick red precipitate. If there is still a brick-red precipitate, then continue to react all the supernatant obtained by the centrifugat...

Embodiment 3

[0050] Example 3 The effect of alginate oligosaccharide derivatives in treating Parkinson's disease

[0051] 1 Experimental materials

[0052] 1.1 Experimental animals

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of mannuronic acid oligose with carboxyl at a 1-position of a reducing end and a derivative to treatment of a Parkinson's disease. The mannuronic acid oligose and the derivative are particularly a compound or a pharmaceutically acceptable salt expressed by the following structural formula (II) in the description, wherein n in the formula (II) is one or more integers from 0-20.

Description

technical field [0001] The invention relates to mannuronic acid oligosaccharides and their derivatives with a carboxyl group at the first reducing end and their application in treating Parkinson's disease. Background technique [0002] Parkinson's disease (PD) is a common neurodegenerative disease that occurs in middle-aged and elderly people over the age of 50-60. The main lesions are in the substantia nigra and striatum pathways, resulting in resting tremor, hypertonia, and bradykinesia. Parkinson's disease is the fourth most common neurodegenerative disorder among older adults, affecting 1% of those over 65 and 0.4% of those over 40. The drugs for the clinical treatment of Parkinson's disease are mainly compound levodopa preparations, dopamine receptor agonists, monoamine oxidase inhibitors, anticholinergic agents and amantadine, etc., but there are disadvantages such as large side effects and long-term application effect decline. [0003] Alginate is the main component...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7016A61K31/702A61K31/734A61P25/16C08B37/04C07H3/04C07H3/06C07H1/00
Inventor 耿美玉辛现良丁健
Owner GREEN VALLEY (SHANGHAI) PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com